North America Ankylosing Spondylitis Market Size & Outlook
North America ankylosing spondylitis market, 2016-2027 (US$M)
Related Markets
North America ankylosing spondylitis market highlights
- The North America ankylosing spondylitis market generated a revenue of USD 2,529.6 million in 2019.
- The market is expected to grow at a CAGR of 7.1% from 2020 to 2027.
- In terms of segment, humira was the largest revenue generating drug in 2019.
- Others Drugs is the most lucrative drug segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2020 to 2027.
North America data book summary
| Market revenue in 2019 | USD 2,529.6 million |
| Market revenue in 2027 | USD 4,392.9 million |
| Growth rate | 7.1% (CAGR from 2019 to 2027) |
| Largest segment | Humira |
| Fastest growing segment | Others Drugs |
| Historical data covered | 2016 - 2018 |
| Base year for estimation | 2019 |
| Forecast period covered | 2020 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others Drugs |
| Key market players worldwide | AbbVie Inc, Amgen Inc, Pfizer Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Johnson & Johnson, Merck & Co Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 60.3% of the global ankylosing spondylitis market in 2019.
- Globally, North America is projected to lead the regional market in terms of revenue in 2027.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,344.1 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ankylosing Spondylitis Market Scope
Ankylosing Spondylitis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America ankylosing spondylitis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ankylosing spondylitis market will help companies and investors design strategic landscapes.
Humira was the largest segment with a revenue share of 25.42% in 2019. Horizon Databook has segmented the North America ankylosing spondylitis market based on cosentyx, humira, simponi, remicade, enbrel, cimzia, others drugs covering the revenue growth of each sub-segment from 2016 to 2027.
- North America Ankylosing Spondylitis Drug Outlook (Revenue, USD Million, 2016-2027)
- Cosentyx
- Humira
- Simponi
- Remicade
- Enbrel
- Cimzia
- Others Drugs
Reasons to subscribe to North America ankylosing spondylitis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America ankylosing spondylitis market databook
-
Our clientele includes a mix of ankylosing spondylitis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America ankylosing spondylitis market, including forecasts for subscribers. This continent databook contains high-level insights into North America ankylosing spondylitis market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
North America ankylosing spondylitis market size, by country, 2016-2027 (US$M)
North America Ankylosing Spondylitis Market Share, 2019 & 2027 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
